T1	Premise 633 839	Diurnal IOP (9:00 am, 1:00 pm, 5:00 pm) was reduced from 25.2 to 16.7 mmHg (33.7%) with lantanoprost and from 25.4 to 17.1 mmHg (32.7%) with timolol as determined at the end of the 6-month treatment period.
T2	Premise 918 1036	Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions.
T3	Premise 1046 1087	both drugs were generally well tolerated.
T4	Premise 1088 1217	The most significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%).
T5	Claim 1218 1277	Timolol caused more systemic side effects than latanoprost.
T6	Claim 1278 1406	Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily.
T7	Claim 1407 1476	Latanoprost was generally well tolerated systemically and in the eye.
R1	Support Arg1:T3 Arg2:T7	
R2	Support Arg1:T1 Arg2:T6	
